Company Performance - OraSure Technologies reported a quarterly loss of $0.01 per share, better than the Zacks Consensus Estimate of a loss of $0.04, and a significant decline from earnings of $0.27 per share a year ago, indicating a 103.7% decrease year-over-year [1] - The company achieved revenues of $39.92 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 1.97%, but down from $89.19 million in the same quarter last year, reflecting a 55.2% decline [2] - Over the last four quarters, OraSure has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Performance - OraSure shares have declined approximately 47.7% since the beginning of the year, contrasting with the S&P 500's gain of 21.2% [3] - The current Zacks Rank for OraSure is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$0.03 on revenues of $38.51 million, while for the current fiscal year, the estimate is $0.05 on revenues of $186.12 million [7] - The outlook for the Medical - Products industry, to which OraSure belongs, is currently in the top 36% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-Q ______________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024. OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________to _________ . Commission File Number 001-16537 ...

| --- | |--------------------------| | | | | | Investor Contact: | | Jason Plagman | | VP, Investor Relations | | investorinfo@orasure.com | Communications EXHIBIT 99.1 | --- | |---------------------| | | | | | | | Media Contact: | | Amy Koch | | Director, Corporate | | media@orasure.com | OraSure Reports Q3 '24 Revenue of $39.9 Million Q3 GAAP EPS of $(0.06); Q3 Non-GAAP EPS of $(0.01) OraQuick® HCV Self-test receives initial orders following receipt of WHO pre-qualification status Expanding Sample Managem ...

Q3 GAAP EPS of $(0.06); Q3 Non-GAAP EPS of $(0.01) OraQuick® HCV Self-test receives initial orders following receipt of WHO pre-qualification status Expanding Sample Management applications into blood proteomics Exiting Risk Assessment testing business to focus on markets with attractive growth opportunities BETHLEHEM, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions, today announced its fina ...

OraSure Technologies Inc. (NASDAQ: OSUR ), a health and wellness company based in Pennsylvania, is a classic Benjamin Graham-style net current asset value-based investment (NCAV). While the discount to NCAV is only slight, it is perhaps worth the price due toI am a value investor with a concentrated portfolio, focusing on rare and exceptional buying opportunities. As a keen reader of Value Investing literature, I am well versed in the teachings of 'super investors' such as Warren Buffett, Charlie Munger, Be ...

BETHLEHEM, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering third quarter 2024 financial results and certain business developments for 5 p.m. ET on November 6, 2024. A webcast of the conference call will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access at least 1 ...

Overview of the Recent Transaction On September 30, 2024, Neuberger Berman Group LI.C, a prominent investment firm, made a significant addition to in investment portfolio by aequiring 3,927,692 shares of OraSure Technologies Inc (OSUR, Financial). This transaction, executed at a price of $4.27 per share, marks a notable increase in the firm's holdings in the medical devices sector. The trade reflects an 8.73% change in the firm's previous stake, emphasizing a strategic move to bolster its position in OraSur ...

BETHLEHEM, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions today announced the election of Jack Kenny to its Board of Directors, effective September 9, 2024. With the addition of Mr. Kenny, OraSure's Board of Directors currently has seven members. Mr. Kenny is the former Chief Executive Officer for Meridian Bioscience, where he led the company's turnaround before it was acquired. He has mor ...

OraSure Technologies Inc (NASDAQ:OSUR) Q2 2024 Results Conference Call August 6, 2024 5:00 PM ET Company Participants Jason Plagman - Vice President-Investor Relations Carrie Eglinton Manner - President and Chief Executive Officer Ken McGrath - Chief Financial Officer Conference Call Participants Casey Woodring - JPMorgan Andrew Cooper - Raymond Jones Operator Good day, and thank you for standing by. Welcome to the OraSure Technologies Incorporated 2024 Second Quarter Earnings Conference Call. At this time, ...

OraSure Technologies (OSUR) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to loss of $0.07 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 133.33%. A quarter ago, it was expected that this diagnostic test maker would post earnings of $0.04 per share when it actually produced earnings of $0.04, delivering no surprise. Over the last four quarters, the ...